333350-83-7

Usage

Uses

Used in Pharmaceutical Industry:
[1,1'-Biphenyl]-4-carboxamide, N-[(4-methylphenyl)methyl]is used as an intermediate in the synthesis of various pharmaceutical compounds for its potential to be modified and tailored to exhibit specific characteristics beneficial for drug development.
Used in Materials Science:
In the field of materials science, [1,1'-Biphenyl]-4-carboxamide, N-[(4-methylphenyl)methyl]is used as a building block for creating new materials with desired properties. Its structure can be manipulated to enhance certain characteristics, making it a valuable component in the development of advanced materials.
Used in Organic Synthesis:
As an intermediate in organic synthesis, [1,1'-Biphenyl]-4-carboxamide, N-[(4-methylphenyl)methyl]is utilized for the creation of a wide range of organic compounds. Its versatility in structure modification allows for the synthesis of various target molecules with specific applications in different industries.

Upstream product

• 104-84-7 para-methylbenzylamine 
• 92-92-2 biphenyl-4-carboxylic acid 

Downstream Products

• 1034734-31-0 biphenylcarbonyl(4-methylbenzyl)carbamic chloride 

Relevant academic research and scientific papers

Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-XLand BCL-2

The BCL-2 family of proteins (including the prosurvival proteins BCL-2, BCL-XL, and MCL-1) is an important target for the development of novel anticancer therapeutics. Despite the challenges of targeting protein-protein interaction (PPI) interfaces with small molecules, a number of inhibitors (called BH3 mimetics) have entered the clinic and the BCL-2 inhibitor, ABT-199/venetoclax, is already proving transformative. For BCL-XL, new validated chemical series are desirable. Here, we outline the crystallography-guided development of a structurally distinct series of BCL-XL/BCL-2 inhibitors based on a benzoylurea scaffold, originally proposed as α-helix mimetics. We describe structure-guided exploration of a cryptic "p5"pocket identified in BCL-XL. This work yields novel inhibitors with submicromolar binding, with marked selectivity toward BCL-XL. Extension into the hydrophobic p2 pocket yielded the most potent inhibitor in the series, binding strongly to BCL-XL and BCL-2 (nanomolar-range half-maximal inhibitory concentration (IC50)) and displaying mechanism-based killing in cells engineered to depend on BCL-XL for survival.

Alpha-helical mimetics

Benzoyl urea derivatives that are alpha helical peptides mimetics that mimic BH3-only proteins, compositions containing them, their conjugation to cell-targeting-moieties, and their use in the regulation of cell death are disclosed. The benzoyl urea derivatives are capable of binding to and neutralizing pro-survival Bcl-2 proteins. Use of benzoyl urea derivatives in the treatment and/or prophylaxis of diseases or conditions associated with deregulation of cell death are also described.

ALPHA-HELICAL MIMETICS

Benzoyl urea derivatives that are alpha helical peptide mimetics that mimic BH3-only proteins, compositions containing them, their conjugation to cell-targeting moieties, and their use in the regulation of cell death are disclosed. The benzoyl urea derivatives are capable of binding to and neutralising pro-survival Bcl-2 proteins. Use of the benzoyl urea derivatives in the treatment and/or prophylaxis of diseases or conditions associated with deregulation of cell death are also disclosed.